TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24800383

Group type: EXPERIMENTAL
Intervention: Email-linked website intervention with ten consecutive weekly emails and two motivational phone calls
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 339
Study: 21780170

Group type: EXPERIMENTAL
Intervention: Maximal voluntary contractions (10 contractions sustained for 20 seconds) with transcranial magnetic stimulation (TMS) delivered at 5 second intervals.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) for assessing central fatigue.
Number of subjects: 10
Study: 19757432

Group type: EXPERIMENTAL
Intervention: Proposed response adaptive design with a variance-penalized criterion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed design
Number of subjects: 0
Study: 17019594

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/day for 2 weeks)
Number of subjects: 18
Study: 15023583

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 17
Study: 11300391

Group type: EXPERIMENTAL
Intervention: Droperidol (20 microg x kg(‐1) body weight)
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 1334
Study: 10211008

Group type: EXPERIMENTAL
Intervention: Propofol infusion at 21, 12 and 6 mg kg‐1 h‐1 for a minimum of 2 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 20
Study: 10150182

Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg b.i.d., oral)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 3127417

Group type: EXPERIMENTAL
Intervention: Highly purified FSH (225 IU daily for 10 days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotropin (hMG; 225 IU daily for 10 days)
Number of subjects: 10
Study: 30277639

Group type: EXPERIMENTAL
Intervention: ABVE-PC chemotherapy followed by response evaluation
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: ABVE-PC chemotherapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Involved field radiotherapy (IFRT) or no further therapy for RERs with CR
Number of subjects: 96
Study: 28855976

Group type: EXPERIMENTAL
Intervention: Hydroxytyrosol (HT) 15 mg/day for 3 weeks
Number of subjects: 0
Study: 26547357

Group type: EXPERIMENTAL
Intervention: Vericiguat 10 mg
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Pooled vericiguat groups (1.25 mg, 2.5 mg, 5 mg, 10 mg)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Vericiguat (various doses)
Number of subjects: 456
Study: 23568622

Group type: EXPERIMENTAL
Intervention: 1-carbamimidoyl-L-proline (CLP)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo lotion
Number of subjects: 126
Study: 20232386

Group type: EXPERIMENTAL
Intervention: Red meat consumption
Number of subjects: 99579

Group type: EXPERIMENTAL
Intervention: Processed meat consumption
Number of subjects: 99579

Group type: EXPERIMENTAL
Intervention: High-temperature cooking methods
Number of subjects: 99579

Group type: EXPERIMENTAL
Intervention: Level of meat doneness
Number of subjects: 99579

Group type: EXPERIMENTAL
Intervention: Intake of specific meat mutagens (MeIQx, DiMeIQx, PhIP, B(a)P)
Number of subjects: 99579

Group type: EXPERIMENTAL
Intervention: Heme iron intake
Number of subjects: 99579
Study: 19062477

Group type: EXPERIMENTAL
Intervention: Manix 600 mg for 13 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Vitamin E 1000 IU for 13 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 55
Study: 16906045

Group type: EXPERIMENTAL
Intervention: 1/Scr
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Cockcroft‐Gault
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: MDRD
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Nankivell
Number of subjects: 148
Study: 15646163

Group type: EXPERIMENTAL
Intervention: Knowledge of the effects of smoking
Number of subjects: 3360

Group type: EXPERIMENTAL
Intervention: Smoking prevalence
Number of subjects: 3360
Study: 11237920

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Needling revision
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (unoperated eye)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 25
Study: 9386082

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) - 10 mg infused in 500 mL of normal saline
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Aprotinin (AP) - High-dose: 280 mg loading dose, 280 mg in CPB prime solution, 70 mg/h for 6 hours
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (P) - Control group for TA
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (P) - Control group for AP
Number of subjects: 101
Study: 8196727

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 3203055

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg rectally as premedication
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no diazepam)
Number of subjects: 21
Study: 30666023

Group type: EXPERIMENTAL
Intervention: Home-based follow-up care (HBFC) intervention administered for 12 months
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Home-based follow-up care (HBFC) intervention
Number of subjects: 299

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 299
Study: 28926762

Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (200mg twice daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 25556220

Group type: EXPERIMENTAL
Intervention: TSS
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MMA
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: D-DLL
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: S-DLL
Number of subjects: 32
Study: 24498826

Group type: EXPERIMENTAL
Intervention: Isotretinoin (0.5 mg/kg/day) + Vitamin E (800 IU/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotretinoin (0.5 mg/kg/day) + Cod liver oil (800 IU/day)
Number of subjects: 60
Study: 22028471

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents or bare metal stents
Number of subjects: 7162

Group type: EXPERIMENTAL
Intervention: Patients with ST
Number of subjects: 7162
Study: 19252250

Group type: EXPERIMENTAL
Intervention: Disease modifying anti-rheumatic drugs (DMARDs), specifically methotrexate (MTX) as the anchor drug.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease modifying anti-rheumatic drugs (DMARDs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 17721621

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no aprotinin)
Number of subjects: 20
Study: 15982605

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Prograf)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Cyclosporine microemulsion (Neoral)
Number of subjects: 129
Study: 11845649

Group type: EXPERIMENTAL
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy techniques
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Psychodynamic and cognitive techniques
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Behavioral techniques
Number of subjects: 63
Study: 9602764

Group type: EXPERIMENTAL
Intervention: ibuprofen for 3 weeks
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: ibuprofen for 1 week and placebo for the next 2 weeks
Number of subjects: 144

Group type: COMPARATOR
Intervention: placebo for 3 weeks
Number of subjects: 144
Study: 8042206

Group type: EXPERIMENTAL
Intervention: 200 mg GM-1 followed by 100 mg GM-1 daily for 10 days and 100 mg GM-1 intramuscularly for 11-21 days
Number of subjects: 792

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: GM-1 (treated within 4 hours)
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: GM-1
Number of subjects: 792
Study: 3281620

Group type: EXPERIMENTAL
Intervention: Diuretic-metoprolol combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose diuretic therapy (100 to 150 mg/d of hydrochlorothiazide)
Number of subjects: 0
Study: 29084488

Group type: EXPERIMENTAL
Intervention: Therapy for depression
Number of subjects: 406
Study: 28746222

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg in 5 mL normal saline (NS)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 105
Study: 26135281

Group type: EXPERIMENTAL
Intervention: Combined intervention consisting of multidimensional early detection strategies with age- and interdisciplinary integrated care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study: 23228505

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Thermal balloon ablation (TBA)
Number of subjects: 58
Study: 20639712

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: n-6 fatty acids
Number of subjects: 43

Group type: COMPARATOR
Intervention: saturated fatty acids (placebo)
Number of subjects: 43
Study: 18582177

Group type: EXPERIMENTAL
Intervention: Risperidone (0.5 to 3.5 mg/day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 16644278

Group type: EXPERIMENTAL
Intervention: ERP word repetition paradigm
Number of subjects: 11

Group type: COMPARATOR
Intervention: Normal controls (NC)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Mild AD group
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both N400 and P600 potentials
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Group discrimination
Number of subjects: 11
Study: 12803353

Group type: EXPERIMENTAL
Intervention: Standardized patients (SPs) portraying patient scenarios
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Standardized patients (SPs) coding physician performance
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Standardized patients (SPs) assessing alcohol consumption and advice against smoking
Number of subjects: 92
Study: 10831925

Group type: COMPARATOR
Intervention: Matrix transdermal 17beta‐estradiol patch
Number of subjects: 569
Study: 8991327

Group type: EXPERIMENTAL
Intervention: Victimization experiences (e.g., sexual abuse, parental assault, kidnapping)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prior psychopathology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parent-child relationship problems
Number of subjects: 0
Study: 1346182

Group type: EXPERIMENTAL
Intervention: Day unit care
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (established practice)
Number of subjects: 54
Study: 6202963

Group type: EXPERIMENTAL
Intervention: Felodipine 12.5 mg t.i.d. for 3 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Felodipine 25 mg t.i.d. for 3 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Felodipine 50 mg t.i.d. for 3 days
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Felodipine (all doses)
Number of subjects: 11
Study: 29947235

Group type: EXPERIMENTAL
Intervention: miRNA group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27829449

Group type: EXPERIMENTAL
Intervention: Behavioral counselling via two 1-h face-to-face sessions and two 15-min telephone calls
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual medical care, written PAD management information sheet, and four 15-min telephone calls with general discussion about PAD symptoms and health and wellbeing
Number of subjects: 200
Study: 23911555

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Colonic cleansing with MoviPrep
Number of subjects: 109

Group type: COMPARATOR
Intervention: Healthy Volunteers (Control)
Number of subjects: 109
Study: 22727475

Group type: EXPERIMENTAL
Intervention: Adaptive AVD
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fixed AVD
Number of subjects: 100
Study: 20386133

Group type: EXPERIMENTAL
Intervention: Accelerometers mounted on each ankle connected to a wearable system for evaluating standing vertical jump.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Accelerometers measuring ankle acceleration during countermovement and squat jumps.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Peak detection algorithm for quantifying flight time from acceleration modulus.
Number of subjects: 51
Study: 18317718

Group type: EXPERIMENTAL
Intervention: BCG-RIVM 2x10^8 CFU in six weekly instillations
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: MMC 20 mg in six weekly instillations
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: MMC 20 mg in six weekly instillations with subsequent monthly instillations for 3 years
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: MMC 20 mg instilled weekly six times
Number of subjects: 627

Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 627
Study: 16008115

Group type: EXPERIMENTAL
Intervention: Kan Jang (Andrographis paniculata and Acanthopanax senticosus)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ginseng (Panax ginseng)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valerian (Valeriana officinalis)
Number of subjects: 0
Study: 12808486

Group type: COMPARATOR
Intervention: Atenolol (50 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nebivolol (5 mg daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg daily) added after 12 weeks
Number of subjects: 30
Study: 10760334

Group type: EXPERIMENTAL
Intervention: PTCA with prolonged perfusion balloon inflation (n = 66)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Elective stenting (n = 31)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: PTCA (n = 66)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: PTCA alone (n = 66)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Crossover-to-stent arm (n = 15)
Number of subjects: 97
Study: 8897119

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX), 0.5 mg at night
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no DEX)
Number of subjects: 74
Study: 1740677

Group type: EXPERIMENTAL
Intervention: Extended-field radiotherapy (RT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: MOPP chemotherapy (CHT)
Number of subjects: 89
Study: 31520525

Group type: EXPERIMENTAL
Intervention: Triheptanoin (1 g/kg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 30064968

Group type: EXPERIMENTAL
Intervention: Encouragement to try the automated digital health intervention via SMS text messages
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no encouragement)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Treatment group who tried the intervention
Number of subjects: 112
Study: 27498095

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 24495529

Group type: EXPERIMENTAL
Intervention: PIRO scores in ICU transfer group (derivation group)
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: PIRO scores in ICU transfer group (validation group)
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Proportion of ICU transfer patients by PIRO score ranges (derivation group)
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Proportion of ICU transfer patients by PIRO score ranges (validation group)
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Inpatient mortality by PIRO score ranges (derivation group)
Number of subjects: 1049

Group type: EXPERIMENTAL
Intervention: Inpatient mortality by PIRO score ranges (validation group)
Number of subjects: 1049
Study: 22796905

Group type: EXPERIMENTAL
Intervention: 13.3 mg/24 h rivastigmine patch
Number of subjects: 567

Group type: COMPARATOR
Intervention: 9.5 mg/24 h rivastigmine patch
Number of subjects: 567
Study: 20951303

Group type: EXPERIMENTAL
Intervention: ProTaper UR
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MTwo R
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hand instrumentation
Number of subjects: 60
Study: 18041917

Group type: EXPERIMENTAL
Intervention: Higher total doses of radiation (1.8-2 Gy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypofractionated regimens (larger daily doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional daily doses (1.8-2 Gy)
Number of subjects: 0
Study: 16360360

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 22
Study: 12058096

Group type: EXPERIMENTAL
Intervention: STN deep brain stimulation (DBS) ON
Number of subjects: 12

Group type: COMPARATOR
Intervention: STN deep brain stimulation (DBS) HALF
Number of subjects: 12

Group type: COMPARATOR
Intervention: STN deep brain stimulation (DBS) OFF
Number of subjects: 12
Study: 10965638

Group type: EXPERIMENTAL
Intervention: Enhanced Behavioral Family Intervention (EBFI)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Standard Behavioral Family Intervention (SBFI)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Self-Directed Behavioral Family Intervention (SDBFI)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Wait List (WL)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: EBFI and SBFI
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: All 3 conditions (EBFI, SBFI, SDBFI)
Number of subjects: 305
Study: 8607589

Group type: EXPERIMENTAL
Intervention: Enoxaparin (30 mg subcutaneously every 12 hours)
Number of subjects: 670

Group type: COMPARATOR
Intervention: Warfarin (adjusted dose, INR 2.0 to 3.0)
Number of subjects: 670

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 670
Study: 1483483

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 2990711

Group type: EXPERIMENTAL
Intervention: Transfer factor (TF) immunotherapy for 18 months in addition to radiotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 100
Study: 30328496

Group type: EXPERIMENTAL
Intervention: Posterior-Stabilized (PS) implants
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medially Congruent (MC) implants
Number of subjects: 100
Study: 30092284

Group type: EXPERIMENTAL
Intervention: Exposure + TILS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure + sham TILS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TILS alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham TILS alone
Number of subjects: 0
Study: 26739268

Group type: EXPERIMENTAL
Intervention: Family-led caregiver-delivered home-based rehabilitation intervention
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 1200
Study: 24493185

Group type: EXPERIMENTAL
Intervention: Knee flexion for six hours post-operatively
Number of subjects: 600

Group type: COMPARATOR
Intervention: Knee flexion for three hours post-operatively
Number of subjects: 600

Group type: COMPARATOR
Intervention: Knee extension
Number of subjects: 600
Study: 22173281

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (37.5 mg/day for 4 days, then 75 mg/day for 6 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine XR (50 mg/day for 10 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Indinavir (800 mg) co-administered on day 12
Number of subjects: 24
Study: 20460139

Group type: EXPERIMENTAL
Intervention: Study pairs that later served as Old pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Study pairs containing words that subsequently appeared in Intra pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accepted Old pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rejected Intra pairs
Number of subjects: 0
Study: 17601187

Group type: EXPERIMENTAL
Intervention: Unilateral subthalamic nucleus (STN) stimulation ON
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus (STN) stimulation ON
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal stimulation OFF
Number of subjects: 0
Study: 15582640

Group type: EXPERIMENTAL
Intervention: Facilitation intervention for implementing Kangaroo Mother Care guidelines
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group with improvement-focused organizational culture
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Change team establishment
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Contextual factors (leadership, staff attitudes)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Learning and behaviour change
Number of subjects: 8
Study: 11853372

Group type: EXPERIMENTAL
Intervention: Monograph for growth disorders
Number of subjects: 336

Group type: COMPARATOR
Intervention: Control group (nurses not receiving the monograph)
Number of subjects: 336
Study: 10190404

Group type: EXPERIMENTAL
Intervention: Combination therapy with metoprolol + felodipine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combination therapy with enalaril + hydrochlorothiazide
Number of subjects: 33
Study: 8547381

Group type: EXPERIMENTAL
Intervention: In-home visits with structured comprehensive geriatric assessment and follow-up by specially trained nurses
Number of subjects: 791
Study: 2367393

Group type: EXPERIMENTAL
Intervention: Ofloxacin 2 X 200 mg orally for 10 days
Number of subjects: 57

Group type: COMPARATOR
Intervention: Established antibiotics
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 57
Study: 31823115

Group type: EXPERIMENTAL
Intervention: ANCOVA with random assignment and multinormal covariates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current ANOVA formula
Number of subjects: 0
Study: 30315500

Group type: EXPERIMENTAL
Intervention: DBT training program
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard care training program
Number of subjects: 57
Study: 28232290

Group type: EXPERIMENTAL
Intervention: Individualized enhanced CBT
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Adolescent Community Reinforcement Approach (ACRA)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Motivational enhancement and cognitive behavioral therapy intervention (MET/CBT-7)
Number of subjects: 161
Study: 25585069

Group type: EXPERIMENTAL
Intervention: Doxycycline prophylaxis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contingency management (CM)
Number of subjects: 30